NCT03046511

Brief Summary

An intraperitoneal implanted catheter is always necessary to perform Peritoneal Dialysis. Catheter insertion has been associated with infectious complication such as Exit Site Infection (ESI), Tunnel Infection and Peritonitis. The last one may lead to loss of the technique because the need of catheter removal. Most of international guidelines recommends the use of prophylactic antibiotics. Different protocols has been used, mostly intravenous single injection before the procedure. For the last 25 years our unit gives a single intraperitoneal dose of Cefazolin immediately after the catheter insertion. The aim of this study is compare the effect of a pre- operative IV dose os Cefazolin with a post- procedure intraperitoneal single dose administration of the same drug.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Mar 2017

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 5, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 8, 2017

Completed
28 days until next milestone

Study Start

First participant enrolled

March 8, 2017

Completed
6.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

February 13, 2023

Status Verified

February 1, 2023

Enrollment Period

6.8 years

First QC Date

February 5, 2017

Last Update Submit

February 8, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Peritonitis

    Peritonitis asscociated catheter defined by cloudy effluent, high leukocyte count with neutrofilia

    14 days

Secondary Outcomes (2)

  • Exit site infection

    14 days

  • Tunnel infection

    14 days

Study Arms (2)

Intraperitoneal

EXPERIMENTAL

One single dose of intraperitoneal Cefazolin 1000 mg via the recently inserted peritoneal catheter

Drug: Cefazolin

Intravenous

ACTIVE COMPARATOR

One single dose of intravenous Cefazolin 1000 mg one hour before catheter insertion

Drug: Cefazolin

Interventions

A post- procedure administration of Cefazolin will be compared with a pre-operative intravenous dose

IntraperitonealIntravenous

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects suffering from Chronic Kidney Disease, candidates to a intra- peritoneal catheter insertion

You may not qualify if:

  • Pregnancy; Active antibiotic treatment before the procedure; Known allergy to Cefazolin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Carmel Medical Center

Haifa, 34362, Israel

RECRUITING

MeSH Terms

Interventions

Cefazolin

Intervention Hierarchy (Ancestors)

Cephalosporinsbeta-LactamsLactamsAmidesOrganic ChemicalsThiazinesSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Victor Frajewicki, MD

    Carmel Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Victor Frajewicki, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head, Department of Nephrology and Hypertension

Study Record Dates

First Submitted

February 5, 2017

First Posted

February 8, 2017

Study Start

March 8, 2017

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

February 13, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will not share

Locations